AVLN · Avalyn Pharma Inc. Common Stock
View on chartInsiders & Stakes
| Novo Holdings A/S 10% Owner | ▲ Buy | Open Market | 3,883,289 Shares held | 5/1/2026 | View profile |
| FMR LLC | ▼ Sell | Other | 2,284,535 Shares held | 5/1/2026 | View profile |
| Jill Carroll | ▲ Buy | Open Market | 2,186,562 Shares held | 5/1/2026 | View profile |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | ▼ Sell | Other | 1,275,486 Shares held | 5/1/2026 | View profile |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 1,122,087 Shares held | 5/1/2026 | View profile |
Transaction History
| Novo Holdings A/S | ▼ Sell | Other | 3,327,734 | — | 5/1/2026 |
| Novo Holdings A/S | ▲ Buy | Open Market | 555,555 | $10.0M | 5/1/2026 |
| FMR LLC | ▼ Sell | Other | 727,585 | — | 5/1/2026 |
| FMR LLC | ▼ Sell | Other | 80,291 | — | 5/1/2026 |
| FMR LLC | ▼ Sell | Other | 225,843 | — | 5/1/2026 |
| FMR LLC | ▼ Sell | Other | 377,948 | — | 5/1/2026 |
| Jill Carroll | ▼ Sell | Other | 1,419,298 | — | 5/1/2026 |
| Jill Carroll | ▼ Sell | Other | 489,486 | — | 5/1/2026 |
| Jill Carroll | ▲ Buy | Open Market | 277,778 | $5.0M | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 1,419,298 | — | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 489,486 | — | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 277,778 | $5.0M | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 354,824 | — | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 489,486 | — | 5/1/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 277,777 | $5.0M | 5/1/2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | ▼ Sell | Other | 1,275,486 | — | 5/1/2026 |
| FMR LLC | ▼ Sell | Other | 872,868 | — | 5/1/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVLN releases Phase 1 data for AP02 inhaled therapy
Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.
AVLN releases Phase 1 data for AP02 inhaled therapy. Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.